University of California, San Francisco School of Medicine (UCSF) 34th Annual Advances in Heart Disease
In-Person Event
Dec 01 - 03, 2017
San Francisco, California, USA
OVERVIEW
University of California, San Francisco School of Medicine (UCSF) 34th Annual Advances in Heart Disease is organized by University of California, San Francisco School of Medicine (UCSF) and will be held during Dec 01 - 03, 2017 at Park Central Hotel San Francisco, San Francisco, California, United States of America.
The target audience for this medical event for cardiovascular specialists, practicing cardiologists, internists, family physicians, cardiovascular and critical care nurses, and paraphysicians. This CME Conference has been approved with a maximum of 17 CME credits.
Course Overview :
This Course will again strive to present topics that highlight new evidencebased medicine findings reported within the last one to two years that impact clinical practice. These will range across a variety of cardiologic subspecialty interests including preventive cardiology, congenital heart disease, interventional cardiology, electrophysiology, cardiac imaging, cardiovascular pharmacotherapy, clinical cardiology, and cardiac surgery. Our faculty will include a distinguished group of visiting academicians from North America together with outstanding teachers and clinicians from the University of California, San Francisco. We plan to offer adequate time after each lecture to facilitate discussion with audience questions directed to the faculty.
Course Objectives :
This course is intended to facilitate changes in practice with respect to:
• Providing the best management of coronary heart disease, hypertension, lipid disorders, diabetes, systolic and diastolic heart failure, atrial fibrillation and flutter, STEMI and non-STEMI, thromboembolic disease;
• Refining considerations for atrial fibrillation, atrial flutter, and ventricular tachycardia ablation;
• Applying the best considerations of percutaneous interventions for valvular heart disease;
• Improving the use of anti-platelet and anti-coagulation therapy for cardiovascular diseases;
• Recognizing risk stratification of cardiovascular disease;
• Optimizing the management of peripheral artery disease and pulmonary hypertension;
• Recognizing that pathophysiology of diseases and treatment options differ among racial and ethnic groups.
Additional details will be posted as soon as they are available.
The target audience for this medical event for cardiovascular specialists, practicing cardiologists, internists, family physicians, cardiovascular and critical care nurses, and paraphysicians. This CME Conference has been approved with a maximum of 17 CME credits.
Course Overview :
This Course will again strive to present topics that highlight new evidencebased medicine findings reported within the last one to two years that impact clinical practice. These will range across a variety of cardiologic subspecialty interests including preventive cardiology, congenital heart disease, interventional cardiology, electrophysiology, cardiac imaging, cardiovascular pharmacotherapy, clinical cardiology, and cardiac surgery. Our faculty will include a distinguished group of visiting academicians from North America together with outstanding teachers and clinicians from the University of California, San Francisco. We plan to offer adequate time after each lecture to facilitate discussion with audience questions directed to the faculty.
Course Objectives :
This course is intended to facilitate changes in practice with respect to:
• Providing the best management of coronary heart disease, hypertension, lipid disorders, diabetes, systolic and diastolic heart failure, atrial fibrillation and flutter, STEMI and non-STEMI, thromboembolic disease;
• Refining considerations for atrial fibrillation, atrial flutter, and ventricular tachycardia ablation;
• Applying the best considerations of percutaneous interventions for valvular heart disease;
• Improving the use of anti-platelet and anti-coagulation therapy for cardiovascular diseases;
• Recognizing risk stratification of cardiovascular disease;
• Optimizing the management of peripheral artery disease and pulmonary hypertension;
• Recognizing that pathophysiology of diseases and treatment options differ among racial and ethnic groups.
Additional details will be posted as soon as they are available.
KEY DATES
01 Dec, 2017
Event Start Date
03 Dec, 2017
Event End Date
SPECIALITIES
CardiologySUGGESTED HOTELS
CONFERENCE VENUE
Park Central Hotel San FranciscoRELATED CONFERENCES & LIVE WEBINARS
Quick Links